Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Travel-related gastrointestinal diseases: Assessment and management.Public health challenges · 2022
   Review
2. Current State and Promising Opportunities on Pharmaceutical Approaches in the Treatment of Polymicrobial Diseases.Pathogens (Basel, Switzerland) · 2021
   Review
3. Health risk of travel for chronic kidney disease patients.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020
   Review

Corrections and comments

• Comment on
  Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.2018
• Comment on
  When should travel medicine practitioners prescribe Rifamycin SV-MXX for self-treatment of travellers' diarrhoea?2019

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as